New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:34 EDTNBYNovaBay announces completion of enrollment in Phase 2 BAYnovation trial
NovaBay announced it has completed enrollment of patients in its global Phase 2b viral conjunctivitis trial, BAYnovation. The trial is investigating NovaBay’s Auriclosene -- NVC-422 -- Ophthalmic Solution as a treatment for adenoviral conjunctivitis, a highly contagious, potentially sight-impairing form of “pink eye”. This condition affects millions of people globally and there is currently no approved treatment available anywhere in the world. NovaBay expects to report results from its trial in mid-2014. BAYnovation is a multi-centered, randomized clinical study that has enrolled patients with adenoviral conjunctivitis in the United States, India, Sri Lanka, and Brazil. Patients were enrolled into the study by 54 clinical investigators, including 18 in the US, 19 in India, 6 in Sri Lanka and 11 in Brazil. BAYnovation was designed to evaluate the efficacy of NovaBay’s Auriclosene Ophthalmic Solution in the treatment of adenoviral infection, specifically clearing the associated red eye and reducing lingering effects left by the infection.
News For NBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
07:08 EDTNBYEye Institute says doctors 'embrace' Avenova for common eye conditions
The Eye Institute, located in Marin County, California, announced that an informal survey of eye doctors shows a major surge in the use of Avenova, a lid & lash hygiene product that was developed by the Eye Institute and NovaBay Pharmaceuticals for eye conditions that affect millions of Americans. In addition, an increasing number of those doctors are writing articles describing why Avenova has been so beneficial to patients.
May 22, 2015
07:04 EDTNBYNovaBay enters $6.86M private placement
Subscribe for More Information
May 18, 2015
06:46 EDTNBYNovaBay to host analyst and investor day
Subscribe for More Information
May 14, 2015
08:08 EDTNBYNovaBay sees representatives becoming increasingly productive
Subscribe for More Information
08:06 EDTNBYNovaBay reports Q1 EPS (9c), consensus (6c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use